Stock Expert AI
ADTX company logo

Aditxt, Inc. (ADTX) — AI Stock Analysis

Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health through immune mapping and reprogramming. Their lead product, AditxtScore, aims to help individuals understand and manage their immune profiles.

Company Overview

TL;DR:

Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health through immune mapping and reprogramming. Their lead product, AditxtScore, aims to help individuals understand and manage their immune profiles.
Aditxt, Inc. is pioneering immune health management with its AditxtScore platform, offering personalized immune profiling and potential therapies for organ transplantation, autoimmune diseases, and allergies, positioning it at the forefront of immune system-focused healthcare solutions.

About ADTX

Aditxt, Inc., established in 2017 and formerly known as ADiTx Therapeutics, is a biotechnology company dedicated to enhancing immune system health through innovative immune mapping and reprogramming technologies. The company's core focus revolves around developing tools and therapies that allow individuals to understand, manage, and monitor their immune profiles. Aditxt's flagship product, AditxtScore, is designed to provide individuals with insights into their immune system's status, enabling them to proactively address potential threats or imbalances. In addition to AditxtScore, the company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that mimics the body's natural process of inducing tolerance to its own tissues. This technology holds promise for treating autoimmune diseases, allergies, and facilitating successful organ transplantation, including skin grafting. Aditxt operates through strategic licensing agreements, including partnerships with Loma Linda University and Leland Stanford Junior University, to advance its research and development efforts. Headquartered in Mountain View, California, Aditxt is committed to transforming immune health management through personalized and innovative solutions.

Investment Thesis

Aditxt presents a notable market position within the biotechnology sector, driven by its innovative approach to immune health management. The company's AditxtScore platform offers a unique value proposition by providing individuals with personalized insights into their immune profiles, potentially leading to early detection and management of immune-related conditions. The development of Apoptotic DNA Immunotherapy (ADi) for organ transplantation, autoimmune diseases, and allergies represents a significant growth catalyst, addressing large and underserved markets. While the company's current financial metrics, including a negative profit margin of -710498.7% and gross margin of -3413.7%, reflect its early stage of development, the potential for future revenue generation through successful commercialization of its products and therapies warrants consideration. Key value drivers include successful clinical trials, regulatory approvals, and strategic partnerships. Investors should note the company's beta of 1.51, indicating higher volatility compared to the market.

Industry Context

Aditxt operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and significant growth potential. The increasing prevalence of autoimmune diseases, allergies, and the growing demand for organ transplantation are driving the need for advanced immune system therapies. Aditxt's focus on immune mapping and reprogramming positions it within a niche market that is expected to experience substantial growth in the coming years. Competitors in this space include companies like AIMD, ANL, APLM, ATHA, and BLRX, each pursuing different approaches to immune modulation and therapy. Aditxt's unique approach to personalized immune profiling and targeted therapies differentiates it from its competitors and provides a competitive edge.
Biotechnology
Healthcare

Growth Opportunities

  • Expansion of AditxtScore Platform: Aditxt can expand the utility of its AditxtScore platform by incorporating additional biomarkers and developing new applications for disease diagnosis and monitoring. The market for personalized diagnostics is projected to reach $133 billion by 2030, presenting a significant opportunity for Aditxt to capture market share through strategic partnerships and product innovation. Timeline: Ongoing.
  • Commercialization of Apoptotic DNA Immunotherapy (ADi): The successful development and commercialization of ADi for organ transplantation, autoimmune diseases, and allergies represents a major growth driver for Aditxt. The market for autoimmune disease therapies is expected to reach $150 billion by 2028, offering a substantial opportunity for ADi to generate revenue. Timeline: 3-5 years.
  • Strategic Partnerships and Collaborations: Aditxt can accelerate its growth by forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers. These partnerships can provide access to funding, expertise, and distribution channels, enabling Aditxt to expand its reach and commercialize its products more effectively. Timeline: Ongoing.
  • Geographic Expansion: Aditxt can expand its operations into new geographic markets, particularly in Europe and Asia, where there is a growing demand for advanced immune system therapies. This expansion can be achieved through strategic partnerships, licensing agreements, or direct investment. Timeline: 2-3 years.
  • Development of New Immune-Based Therapies: Aditxt can leverage its expertise in immune mapping and reprogramming to develop new therapies for a wide range of diseases, including cancer, infectious diseases, and inflammatory disorders. This diversification can reduce the company's reliance on its existing product pipeline and create new revenue streams. Timeline: 5+ years.
  • AditxtScore platform offers personalized immune profiling, a novel approach to immune health management.
  • Apoptotic DNA Immunotherapy (ADi) targets large markets in organ transplantation, autoimmune diseases, and allergies.
  • Strategic licensing agreements with Loma Linda University and Leland Stanford Junior University provide access to key technologies and expertise.
  • Change in company name in July 2021 reflects strategic shift and focus on immune health.
  • Headquartered in Mountain View, California, a hub for biotechnology innovation.

What They Do

  • Develops AditxtScore for immune profiling.
  • Creates technologies for immune system health improvement.
  • Focuses on immune mapping and reprogramming.
  • Develops Apoptotic DNA Immunotherapy (ADi).
  • Targets organ transplantation applications.
  • Addresses autoimmune diseases and allergies.

Business Model

  • Develops and commercializes immune-related diagnostic and therapeutic products.
  • Generates revenue through sales of AditxtScore and ADi therapies.
  • Forms strategic partnerships and licensing agreements.
  • Conducts research and development to expand its product pipeline.
  • Individuals seeking to understand and manage their immune profiles.
  • Patients with autoimmune diseases, allergies, or in need of organ transplantation.
  • Healthcare providers and research institutions.
  • Pharmaceutical companies seeking to collaborate on immune-based therapies.
  • Proprietary AditxtScore platform for personalized immune profiling.
  • Innovative Apoptotic DNA Immunotherapy (ADi) technology.
  • Strategic licensing agreements with leading universities.
  • Expertise in immune mapping and reprogramming.

Catalysts

  • Upcoming: Clinical trial results for ADi in organ transplantation (Timeline: 12-18 months).
  • Upcoming: Regulatory approvals for AditxtScore in new markets (Timeline: 6-12 months).
  • Ongoing: Strategic partnerships with pharmaceutical companies (Timeline: Ongoing).
  • Ongoing: Expansion of AditxtScore platform with new biomarkers (Timeline: Ongoing).

Risks

  • Potential: Dilution of existing shareholders through future fundraising efforts.
  • Ongoing: High cash burn rate and limited financial resources.
  • Potential: Regulatory hurdles and clinical trial failures.
  • Potential: Competition from established biotechnology companies.
  • Ongoing: Intellectual property challenges and patent disputes.

Strengths

  • Innovative AditxtScore platform for personalized immune profiling.
  • Proprietary Apoptotic DNA Immunotherapy (ADi) technology.
  • Strategic partnerships with leading universities.
  • Experienced management team with expertise in biotechnology.

Weaknesses

  • Limited financial resources and high cash burn rate.
  • Early stage of development and limited commercialization experience.
  • Reliance on strategic partnerships for funding and expertise.
  • Negative profit and gross margins.

Opportunities

  • Expansion of AditxtScore platform into new markets and applications.
  • Commercialization of ADi for organ transplantation, autoimmune diseases, and allergies.
  • Strategic partnerships with pharmaceutical companies and healthcare providers.
  • Geographic expansion into Europe and Asia.

Threats

  • Competition from established biotechnology companies.
  • Regulatory hurdles and clinical trial risks.
  • Intellectual property challenges.
  • Economic downturn and reduced healthcare spending.

Competitors & Peers

  • Ainos, Inc. — Focuses on point-of-care diagnostics and medical devices. — (AIMD)
  • AnPac Bio-Medical Science Co., Ltd. — Develops early cancer screening and detection technologies. — (ANL)
  • Apeiron Therapeutics, Inc. — Focuses on developing novel cancer immunotherapies. — (APLM)
  • Athira Pharma, Inc. — Develops small molecules to restore neuronal health. — (ATHA)
  • BioLineRx Ltd. — Develops oncology and immunology therapeutics. — (BLRX)

Key Metrics

  • Price: $0.88 (-3.30%)
  • Market Cap: $3
  • Volume: NaN
  • MoonshotScore: 44/100

常见问题

What does Aditxt, Inc. (ADTX) do?

Aditxt, Inc. is a biotechnology company focused on developing technologies to improve immune system health. Their primary focus is on immune mapping and reprogramming, with their lead product being AditxtScore, a platform designed to allow individuals to understand, manage, and monitor their immune profiles. Additionally, they are developing Apoptotic DNA Immunotherapy (ADi) for treating autoimmune diseases, allergies, and facilitating successful organ transplantation. Aditxt aims to revolutionize immune health management through personalized and innovative solutions.

Is ADTX stock a good buy?

Evaluating whether ADTX stock is a good buy requires considering its potential and risks. The company's innovative approach to immune health management with AditxtScore and ADi presents significant growth opportunities. However, the company's current financial metrics, including negative profit and gross margins, reflect its early stage of development. Investors should carefully assess the company's ability to secure funding, achieve clinical trial success, and navigate regulatory hurdles before making an investment decision. The high beta of 1.51 also suggests higher volatility.

What are the risks of investing in ADTX?

Investing in ADTX carries several risks inherent to early-stage biotechnology companies. A significant risk is potential dilution of existing shareholders through future fundraising efforts, as the company requires capital to fund its research and development activities. The company also faces a high cash burn rate and limited financial resources, which could impact its ability to execute its business plan. Furthermore, regulatory hurdles and the possibility of clinical trial failures pose substantial risks to the successful development and commercialization of its products. Competition from established biotechnology companies and potential intellectual property challenges also present ongoing risks.

What catalysts could move ADTX stock?

Several catalysts could potentially move ADTX stock in the near to medium term. Positive clinical trial results for ADi in organ transplantation would be a significant catalyst, demonstrating the efficacy and safety of the therapy. Regulatory approvals for AditxtScore in new markets could also drive stock appreciation by expanding the platform's reach and revenue potential. Strategic partnerships with pharmaceutical companies could provide access to funding, expertise, and distribution channels, further boosting investor confidence. Ongoing expansion of the AditxtScore platform with new biomarkers could also enhance its value proposition and attract new customers.

What is ADTX stock price target?

As of March 2, 2026, there is no readily available analyst consensus price target for ADTX stock, likely due to its micro-cap status and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of the company's future revenue potential, expenses, and discount rate, considering the inherent uncertainties associated with biotechnology investments. Investors should conduct their own due diligence and consider the company's growth prospects, risks, and financial position when assessing its potential value.

Is ADTX a good investment right now?

Use the AI score and analyst targets on this page to evaluate Aditxt, Inc. (ADTX). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for ADTX?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Aditxt, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find ADTX financial statements?

Aditxt, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.